Precision Biosensor

Precision Biosensor Days Payable Outstanding

The Days Payable Outstanding (DPO) of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is 18.94. In the previous year, Days Payable Outstanding (DPO) was 21.25 — a change of -10.88% (lower).

Days Payable Outstanding

18.94

YoY

-10.88%

Last updated:

Days Payable Outstanding (DPO) of Precision Biosensor is 2025 18.94 . Days Payable Outstanding (DPO) of Precision Biosensor was 2024 21.25 . It decreases by -10.88% lower compared to the previous year.

The Precision Biosensor Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2020
84.02 KRW
Jan 1, 2021
29.21 KRW
Jan 1, 2022
20.49 KRW
Jan 1, 2023
16.43 KRW
Jan 1, 2024
21.25 KRW
Jan 1, 2025
18.94 KRW
The Precision Biosensor Days Payable Outstanding history
YEARDays Payable OutstandingYoY
18.94-10.88%
21.25+29.36%
16.43-19.81%
20.49-29.86%
29.21-65.24%
84.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

Days Payable Outstanding (DPO) of Precision Biosensor is 18.94 in 2025.

Days Payable Outstanding (DPO) of Precision Biosensor changed from 21.25 to 18.94, representing a -10.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Precision Biosensor with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Precision Biosensor

All Key Metrics — Precision Biosensor